Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helly Hammer

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
BMC Medicine|April 6, 2025
Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event dataMarine Massy, Stefanie Marti, Helly Hammer, et al.
Therapeutische Umschau. Revue Therapeutique|July 22, 2021
[Healthy diet in primary and secondary prevention of stroke]Antonela Bicvic, Helly Hammer, Hakan Sarikaya, et al.
CNS Neuroscience & Therapeutics|January 21, 2022
Application of the "risk of ambulatory disability" (RoAD) score in a "real-world" single-center multiple sclerosis cohortMaximilian Pistor, Helly Hammer, Anke Salmen, et al.
European Journal of Neurology|June 26, 2024
Sex- and age-related shift of relapse phenotypes in a cohort of relapsing multiple sclerosis patients: Post hoc analysis from the OPERA phase 3 trialsA Leon Betancourt, Robert Hoepner, Helly Hammer, et al.
International Review of Neurobiology|August 29, 2022
Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD)Lara Diem, Helly Hammer, Robert Hoepner, et al.
JAMA Network Open|November 29, 2023
Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple SclerosisStefanie Marti, Andreas G F Hoepner, Helly Hammer, et al.
Therapeutische Umschau. Revue Therapeutique|May 18, 2022
[Primary CNS Vasculitis - An Overview]Helly Hammer, Nicole Kamber, Christoph Friedli, et al.
Cureus|August 18, 2025
Neurological and Immunological Insights Into Post-COVID-19 Syndrome: A Single-Center Retrospective StudyLara Diem, Simona Daepp, Vincenzo P Introcaso, et al.
Therapeutic Advances in Neurological Disorders|May 28, 2021
Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapiesChristoph Friedli, Lara Diem, Helly Hammer, et al.
Wiener Klinische Wochenschrift|June 15, 2026
Monitoring physical activity by fitness tracking devices : Usage, acceptance and willingness to share data in patients with multiple sclerosisHelly Hammer, Robert Hoepner, Marie Louise Aicher, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
BMC Medicine|April 6, 2025
Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event dataMarine Massy, Stefanie Marti, Helly Hammer, et al.
Therapeutische Umschau. Revue Therapeutique|July 22, 2021
[Healthy diet in primary and secondary prevention of stroke]Antonela Bicvic, Helly Hammer, Hakan Sarikaya, et al.
CNS Neuroscience & Therapeutics|January 21, 2022
Application of the "risk of ambulatory disability" (RoAD) score in a "real-world" single-center multiple sclerosis cohortMaximilian Pistor, Helly Hammer, Anke Salmen, et al.
European Journal of Neurology|June 26, 2024
Sex- and age-related shift of relapse phenotypes in a cohort of relapsing multiple sclerosis patients: Post hoc analysis from the OPERA phase 3 trialsA Leon Betancourt, Robert Hoepner, Helly Hammer, et al.
International Review of Neurobiology|August 29, 2022
Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD)Lara Diem, Helly Hammer, Robert Hoepner, et al.
JAMA Network Open|November 29, 2023
Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple SclerosisStefanie Marti, Andreas G F Hoepner, Helly Hammer, et al.
Therapeutische Umschau. Revue Therapeutique|May 18, 2022
[Primary CNS Vasculitis - An Overview]Helly Hammer, Nicole Kamber, Christoph Friedli, et al.
Cureus|August 18, 2025
Neurological and Immunological Insights Into Post-COVID-19 Syndrome: A Single-Center Retrospective StudyLara Diem, Simona Daepp, Vincenzo P Introcaso, et al.
Therapeutic Advances in Neurological Disorders|May 28, 2021
Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapiesChristoph Friedli, Lara Diem, Helly Hammer, et al.
Wiener Klinische Wochenschrift|June 15, 2026
Monitoring physical activity by fitness tracking devices : Usage, acceptance and willingness to share data in patients with multiple sclerosisHelly Hammer, Robert Hoepner, Marie Louise Aicher, et al.
Pageof 3